Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Evaluation of Treatments for the Vaccination against Hepatitis B+Thymopentine

      a , b , b , c

      Nephron

      S. Karger AG

      Dialysis, Thymopentine, Hepatitis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We have studied a series of 43 patients – who were suffering from uremia, subject to hemodialysis treatment, resulting seronegative to the test for HBV and who had never been vaccinated before – considering the HBS antibody as seroconversion index. We subdivided our patients into three groups, according to the treatment employed. First group: French vaccine; 2nd group: French vaccine + thymopenthine; 3rd group: recombining DNA vaccine + thymopentine. From a statistical point of view, in the 3rd group we obtained a significant seroconversion in terms of patients, if compared with the other groups.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          978-3-8055-5621-7
          978-3-318-01691-8
          1660-8151
          2235-3186
          1992
          1992
          11 December 2008
          : 61
          : 3
          : 371-372
          Affiliations
          aDepartment of Nephrology and Dialysis, USLN. 1; bDepartment of Nephrology and Dialysis, USL N. 4; cDivision of Nephrology and Dialysis, USL N. 3, Liguria-Ventimiglia, Italy
          Article
          186949 Nephron 1992;61:371–372
          10.1159/000186949
          1386912
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 2
          Categories
          A Special Issue on Virus Hepatitis and the Kidney

          Cardiovascular Medicine, Nephrology

          Hepatitis, Thymopentine, Dialysis

          Comments

          Comment on this article